Although rare, invasive aspergillosis (IA) and invasive mucormycosis (IM) pose a lethal threat to immunocompromised children. The armamentarium to safely treat these fungal infections is limited. Therefore, the recent expanded indication for isavuconazonium sulfate (Cresemba, Astellas), a prodrug of isavuconazole, to treat children 12 months and older infected with IA and IM represents a major opportunity for clinicians to better serve their patients.
“To date, isavuconazole has proven to